全文获取类型
收费全文 | 2030篇 |
免费 | 204篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 36篇 |
妇产科学 | 27篇 |
基础医学 | 287篇 |
口腔科学 | 18篇 |
临床医学 | 214篇 |
内科学 | 348篇 |
皮肤病学 | 36篇 |
神经病学 | 92篇 |
特种医学 | 182篇 |
外科学 | 258篇 |
综合类 | 58篇 |
一般理论 | 1篇 |
预防医学 | 248篇 |
眼科学 | 157篇 |
药学 | 99篇 |
中国医学 | 3篇 |
肿瘤学 | 176篇 |
出版年
2022年 | 12篇 |
2021年 | 27篇 |
2020年 | 14篇 |
2019年 | 29篇 |
2018年 | 52篇 |
2017年 | 36篇 |
2016年 | 43篇 |
2015年 | 45篇 |
2014年 | 69篇 |
2013年 | 99篇 |
2012年 | 116篇 |
2011年 | 113篇 |
2010年 | 56篇 |
2009年 | 64篇 |
2008年 | 115篇 |
2007年 | 103篇 |
2006年 | 107篇 |
2005年 | 110篇 |
2004年 | 98篇 |
2003年 | 114篇 |
2002年 | 103篇 |
2001年 | 45篇 |
2000年 | 26篇 |
1999年 | 34篇 |
1998年 | 43篇 |
1997年 | 23篇 |
1996年 | 20篇 |
1995年 | 22篇 |
1994年 | 24篇 |
1993年 | 21篇 |
1992年 | 21篇 |
1991年 | 13篇 |
1990年 | 17篇 |
1989年 | 14篇 |
1988年 | 16篇 |
1987年 | 19篇 |
1986年 | 13篇 |
1984年 | 15篇 |
1983年 | 14篇 |
1982年 | 14篇 |
1980年 | 14篇 |
1979年 | 18篇 |
1978年 | 15篇 |
1977年 | 15篇 |
1975年 | 13篇 |
1974年 | 12篇 |
1948年 | 11篇 |
1947年 | 13篇 |
1946年 | 16篇 |
1945年 | 14篇 |
排序方式: 共有2242条查询结果,搜索用时 15 毫秒
1.
2.
3.
Intratemporal vascular tumors: detection with CT and MR imaging 总被引:1,自引:0,他引:1
Lo WW; Shelton C; Waluch V; Solti-Bohman LG; Carberry JN; Brackmann DE; Wade CT 《Radiology》1989,171(2):445-448
The diagnostic contributions of computed tomography (CT) and magnetic resonance (MR) imaging were compared in 12 patients with benign intratemporal vascular tumors (hemangioma or vascular malformation). The tumors included six in the internal acoustic canal and six in the geniculate ganglion region. Clinical and histologic correlations were made. Two of the six patients with tumors in the internal acoustic canal underwent CT, and both required gas cisternography to show the tumor. Five patients in that group underwent MR imaging, and all five studies showed the tumor. All six patients with geniculate ganglion tumors underwent CT. Results in one study were questionable, and five showed the tumor. Five patients in this group underwent MR imaging, but the MR findings were positive in only two cases. MR imaging should therefore be performed before CT in the evaluation of facial nerve dysfunction, as it demonstrated all tumors in the internal acoustic canal and some in the geniculate ganglion region. If MR findings are negative, CT should then be performed to rule out a possible geniculate ganglion lesion. 相似文献
4.
5.
W J Thompson P S Anderson S F Britcher T A Lyle J E Thies C A Magill S L Varga J E Schwering P A Lyle M E Christy 《Journal of medicinal chemistry》1990,33(2):789-808
A series of 73 dibenzo[a,d]cycloalkenimines were synthesized and evaluated for their ability to displace (+)-10,11-dihydro-5-methyl-5H-dibenzo[a,d]cyclohepten-5,10-imine ([3H]-(+)-10) from its specific binding site on rat cortical membranes. A number of the more active compounds (Ki ranging from 0.006 to 0.21 microM) were evaluated for N-methyl-D-aspartate (NMDA) antagonist activity in the rat cortical slice (Kb ranging from 0.08 to 0.9 microM) and anticonvulsant activity in the mouse against NMDA induced convulsions. The ED50 values ranged from 0.22 to 7.76 mg/kg and correlated reasonably well with the Kb determination. In the dibenzo[a,d]cyclohepten-5,10-imine series, the (+)-5S,10R enantiomer displayed consistently higher levels of biological activity. While substitution at the 3-position of (+)-10 with electronegative atoms generally increased in vitro activity, a loss of potency relative to (+)-10 (MK-801) was observed in vivo for all of the compounds tested. 相似文献
6.
Charles R. Ashby Yoshio Minabe Alon Toor Lyle D. Fishkin Martin I. Granoff Rex Y. Wang 《Drug development research》1994,31(3):228-236
This study examined the effect of acute and chronic administration of the selective 5-HT3 receptor antagonist BRL 46470A, an analog of granisetron, on the number of spontaneously active dopamine (DA) cells in the substantia nigra pars compacta (A9 or SNC) and the ventral tegmental area (A10 or VTA) in the rat. In the A10 area, the acute administration of BRL 46470A decreased the number of spontaneously active DA cells at a dose of 0.1 mg/kg (0.28 μmol/kg) ip, yet increased the number of spontaneously active DA cells at a dose of 0.3 mg/kg (0.84 μmol/kg). The chronic administration (21 days) of BRL 46470A appeared to produce a multiphasic dose-response curve. Thus, the chronic treatment with BRL 46470A increased the number of spontaneously active A10 DA cells at 0.03 (0.084 μmol) and 0.3 mg/kg, but decreased the number of spontaneously active A10 DA cells at a dose of 0.1 mg/kg. In contrast, BRL 46470A did not decrease the number of spontaneously active A9 DA cells after either acute or chronic administration (0.01-0.3 mg/kg). However, BRL 46470A did increase the number of spontaneously active A9 DA cells at acute and chronic doses similar to those that were effective in A10. The iv administration of (+)-apomorphine (APO) not only failed to reverse the decrease produced by chronic administration of BRL 46470A at 0.1 mg/kg, but further decreased the number of spontaneously active A10 DA cells. Similar to the results obtained with granisetron, the pretreatment of naive rats with either 0.01 or 0.1 mg/kg iv of BRL 46470A significantly potentiated (2-fold) the suppressant action of APO on the basal firing rate of A10, but not A9 DA cells. Overall, our results indicate that similar to granisetron, chronic BRL 46470A at 0.1 mg/kg selectively decreases the number of spontaneously active A10 DA cells, via a mechanism not related to depolarization inactivation. Presently, it is not clear what factors may contribute to the multiphasic dose-response curve of BRL 46470A. © 1994 Wiley-Liss, Inc. 相似文献
7.
骨巨细胞瘤的MRI诊断价值 总被引:10,自引:0,他引:10
目的探讨骨巨细胞瘤的MRI表现特点及其病理基础。资料与方法搜集经手术病理证实的12例骨巨细胞瘤患者资料,分析其MRI征象并与病理结果对照。结果T1WI上肿瘤实体表现为低、等信号,T2WI上为不均匀高信号,Gd-DTPA增强扫描呈中度到明显强化。此外,MRI还可显示肿瘤内坏死、出血、含铁血黄素沉着等。结论MRI能够提供比较全面的影像学信息,可提高对骨巨细胞瘤诊断的准确性。 相似文献
8.
9.
M. C. Robson MD a ; L. G. Phillip MD ; D. M. Cooper RN PhD a ; W. G. Lyle MD ; L. E. Robson RN MS ; L. Odom RN ; D. P. Hill PharmD ; A. F. Hanham MD ; G. A. Ksander MS 《Wound repair and regeneration》1995,3(2):157-167
Transforming growth factor-beta(2) promotes healing in a variety of animal models and exhibits clinical effects thought to be mediated by connective tissue formation. Two clinical trials were conducted to evaluate the safety and effect of transforming growth factor-beta(2) purified from bovine bone and delivered topically to venous stasis ulcers three times per week for up to 6 weeks by means of a lyophilized collagen vehicle. The first was an open-label trial comparing transforming growth factor-beta(2) purified from bovine bone (0.5 microg/cm(2)) with a placebo consisting of lyophilized collagen vehicle-without active drug. After no safety issues arose in that trial, a prospectively randomized, closed-label, observer-blinded, three-armed trial was conducted to compare bovine transforming growth factor-beta(2) (2.5 microg/cm(2)) with the collagen matrix placebo vehicle and with a standard dressing. Standardized elastic compression was applied to all test extremities. The rate of reduction of ulcer area as measured by planimetry was the primary measure of effect. No serious safety-related events occurred in either trial. Clinical evaluation suggested that improvement in the quality and quantity of granulation tissue appeared to precede epithelialization of ulcers treated with bovine transforming growth factor-beta(2). In both studies, treatment with bovine transforming growth factor-beta(2) appeared to have a positive effect on the rate of ulcer closure, whereas ulcers in the control groups continued to exhibit impaired healing. In the open-label study, the mean rate of closure of ulcers treated with bovine transforming growth factor-beta(2) was significantly greater than that of ulcers treated with placebo. There was likewise enhanced reduction in ulcer area in the ulcers treated with bovine transforming growth factor-beta(2) in the second trial. However, because of a higher variability in patient response and a greater placebo effect, the difference was not significant. The placebo was not worse than the standard care arm, thereby showing that the vehicle is not injurious to healing. The combined results of the two trials suggest that, at doses of 0.5 to 2.5 microg/cm(2), bovine transforming growth factor-beta(2) is safe as a topically applied agent in a collagen matrix vehicle and can have a positive effect on closure of venous stasis ulcers. Large multicenter trials appear to be indicated to evaluate fully the potential utility of transforming growth factor-beta(2) in accelerating closure of chronic dermal ulcers. 相似文献
10.